Louis Brenner

Louis Brenner joined Hopewell as President and Chief Executive Officer and a Member of its Board of Directors in November of 2022. Dr. Brenner brings over 20 years of experience in the biotechnology industry and a proven track record in building scientific, clinical and corporate organizations that have successfully navigated all aspects of the product development cycle.
 
Prior to joining Hopewell, Dr. Brenner served as President and CEO of Allena Pharmaceuticals where he catalyzed the company’s progression from a private, early-stage to a public, late-stage development company with multiple homegrown assets in Phase 2 and Phase 3 development. At Allena, he completed multiple financings including a crossover round, an IPO and multiple secondary offerings. Previously, he worked as Chief Medical Officer at Idera Pharmaceuticals, where he assembled a development stage portfolio of nucleic acid therapeutics for cancer and autoimmune diseases, and as Chief Medical officer of Radius Health, where he supervised the successful Phase 3 Global Osteoporosis program for abaloparatide, now marketed as Tymlos. As Senior Vice President at AMAG Pharmaceuticals, he oversaw the Phase 3 program, regulatory filing, and launch of the IV iron product Feraheme. Additionally, Dr. Brenner was a key member of the management teams of the Renal and Transplant Business Units at Genzyme, where he contributed to the success of the blockbuster hyperphosphatemia Renagel/Renvela franchise. There, he led the acquisitions of Bone Care International and Anormed, bringing the additional products of Hectorol for metabolic bone disease and Mozobil for stem cell mobilization to the company’s portfolio. He has previously served as Chairman of the Board of the National Kidney Foundation Affiliate for the New England region and as a Director for PLC Medical Systems and Goldfinch Bio.

Dr. Brenner completed his residency in internal medicine at Brigham and Women’s Hospital and his fellowship in nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital. He holds clinical appointments at Brigham and Women’s Hospital and Dana Farber Cancer Institute. Dr. Brenner earned a B.S. in Biology from Yale University, an M.D. from Duke University and an M.B.A. from Harvard Business School.